皓元医药12万股解除限售条件达成

财中社2025-07-18

7月18日，皓元医药（688131）发布公告，2023年限制性股票激励计划第一类限制性股票第二个解除限售期解除限售条件已成就。符合解除限售条件的激励对象共6名，可解除限售的限制性股票12万股。此次解除限售的条件包括公司未发生财务报告被否定意见及激励对象未被认定为不适当人选等。本次激励计划的第一类限制性股票授予数量为17万股，约占公司总股本的0.11%。根据业绩考核要求，2024年营业收入增长率需不...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2552088498?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-18 19:27","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2552088498","market":"sh","top_or_hot":-1,"title":"皓元医药12万股解除限售条件达成","media":"财中社","content":"<div>\n<p>7月18日，皓元医药（688131）发布公告，2023年限制性股票激励计划第一类限制性股票第二个解除限售期解除限售条件已成就。符合解除限售条件的激励对象共6名，可解除限售的限制性股票12万股。此次解除限售的条件包括公司未发生财务报告被否定意见及激励对象未被认定为不适当人选等。本次激励计划的第一类限制性股票授予数量为17万股，约占公司总股本的0.11%。根据业绩考核要求，2024年营业收入增长率需不...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071819281197ab1053&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>皓元医药12万股解除限售条件达成</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n皓元医药12万股解除限售条件达成\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-18 19:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071819281197ab1053&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月18日，皓元医药（688131）发布公告，2023年限制性股票激励计划第一类限制性股票第二个解除限售期解除限售条件已成就。符合解除限售条件的激励对象共6名，可解除限售的限制性股票12万股。此次解除限售的条件包括公司未发生财务报告被否定意见及激励对象未被认定为不适当人选等。本次激励计划的第一类限制性股票授予数量为17万股，约占公司总股本的0.11%。根据业绩考核要求，2024年营业收入增长率需不...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071819281197ab1053&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688131","symbol_name":"皓元医药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071819281197ab1053&s=b","article_id":"2552088498","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071819281197ab1053&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2552088498","pubTimestamp":1752838037,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"7月18日，皓元医药发布公告，2023年限制性股票激励计划第一类限制性股票第二个解除限售期解除限售条件已成就。此次解除限售的条件包括公司未发生财务报告被否定意见及激励对象未被认定为不适当人选等。本次激励计划的第一类限制性股票授予数量为17万股，约占公司总股本的0.11%。此次解除限售的股票数量占截至2025年7月17日公司总股本的0.06%。2025年一季度，皓元医药实现收入6.06亿元，归母净利润6238万元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688131":"皓元医药","BK0216":"研究试验"},"translate_title":"Haoyuan Pharmaceutical's 120,000 shares have been lifted from sales restrictions","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688131":1},"content_text":"7月18日，皓元医药（688131）发布公告，2023年限制性股票激励计划第一类限制性股票第二个解除限售期解除限售条件已成就。符合解除限售条件的激励对象共6名，可解除限售的限制性股票12万股。此次解除限售的条件包括公司未发生财务报告被否定意见及激励对象未被认定为不适当人选等。本次激励计划的第一类限制性股票授予数量为17万股，约占公司总股本的0.11%。根据业绩考核要求，2024年营业收入增长率需不低于60%，实际增长率为67.16%，符合要求，激励对象的个人绩效考核结果均为“优秀A”或“良好B”，个人层面解除限售比例为100%。此次解除限售的股票数量占截至2025年7月17日公司总股本的0.06%。2025年一季度，皓元医药实现收入6.06亿元，归母净利润6238万元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552088498","isCrawlerRequest":true}